Leukemia

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

By

CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

By

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

By

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

By

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

By

Men have approximately double the incidence rate, are more likely to have progressive and treatment-resistant disease, and have a poorer prognosis compared with women with CLL.

Pediatric CML: Life-Long Considerations With TKI Therapy

Pediatric CML: Life-Long Considerations With TKI Therapy

By

Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

By

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

By

Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

By

Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.

AML: Somatic Mutation Clearance May Be Prognostic for Survival

AML: Somatic Mutation Clearance May Be Prognostic for Survival

By

Researchers determined 3 levels of somatic mutation clearance based on VAF of residual mutations at CR.

Leukemia Treatment Regimens: Acute Myeloid Leukemia (AML)

Get the latest treatment regimens for acute myeloid leukemia (AML), such as induction therapy, consolidation therapy, and more.

Infections: A Cause for Concern Among Patients With CLL

Infections: A Cause for Concern Among Patients With CLL

By

Patients with CLL may have both disease-associated and systemic treatment-associated immune dysfunction, leaving them vulnerable to infection.

FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma

FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma

By

The FDA is reviewing a New Drug Application, which is requesting full approval for CLL/SLL and accelerated approval for follicular lymphoma.

Measurable Residual Disease After Induction May Predict Outcomes in Acute Myeloid Leukemia

Measurable Residual Disease After Induction May Predict Outcomes in Acute Myeloid Leukemia

By

Findings from previous studies suggests that multiparameter flow cytometric minimal residual disease may be used to predict outcomes in acute myeloid leukemia.

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

By

One study's results may be especially relevant for patients eligible for treatment discontinuation.

In Focus: Voxtalisib for CLL and B-Cell Lymphomas

In Focus: Voxtalisib for CLL and B-Cell Lymphomas

By

Voxtalisib is a potent inhibitor of 4 PI3K isoforms (p110α, p110β, p110γ, and p110δ) and a weaker inhibitor of mTOR.

FDA Approves Nilotinib for Pediatric Patients With CML

FDA Approves Nilotinib for Pediatric Patients With CML

By

Patients one year or older are now eligible to receive the drug.

CLL: Venetoclax Plus Rituximab Improves 2-Year PFS

CLL: Venetoclax Plus Rituximab Improves 2-Year PFS

By

Patients in the venetoclax arm had a grade 3 or 4 tumor lysis syndrome rate of 3.1%.

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

By

Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

By

A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

By

A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.

CML: Managing TKI-Related Toxicity To Yield the Best Outcomes

CML: Managing TKI-Related Toxicity To Yield the Best Outcomes

By

Preparing patients for treatment toxicity is important for ensuring that mild or moderate reactions do not undermine adherence.

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

By

The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.

Inotuzumab Ozogamicin May Improve Quality of Life in B-cell Acute Lymphocytic Leukemia

Inotuzumab Ozogamicin May Improve Quality of Life in B-cell Acute Lymphocytic Leukemia

By

Previous studies demonstrated that inotuzumab ozogamicin significantly improves clinical outcomes vs standard of care chemotherapy, but impact on QoL was unknown.

Dasatinib: A Safe and Effective Option for Pediatric CML

Dasatinib: A Safe and Effective Option for Pediatric CML

By

Previous studies have shown that dasatinib may be an effective therapeutic alternative to imatinib.

Isn't Leukemia Still Cancer?

Isn't Leukemia Still Cancer?

By

Approaching leukemia today as only a "liquid" cancer in all cases is to overlook knowledge long available about its tumor phenotype.

Umbralisib: A Promising Therapy for Hematologic Malignancies

Umbralisib: A Promising Therapy for Hematologic Malignancies

By

Umbralisib has shown improved isoform selectivity over currently used PI3Kδ inhibitors.

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing []

Pediatric CML: Imatinib Effective in the Front Line

Pediatric CML: Imatinib Effective in the Front Line

By

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Acute lymphoblastic leukemia disease burden associated with safety and efficacy of CD19-CAR therapy

1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence []

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs